St. Luke’s joins cancer research alliance

St. Luke’s University Health Network (SLUHN) has joined the Caris’ Precision Oncology Alliance (POA). 

The alliance, created by Caris Life Sciences, a molecular science and technology company, is a growing network of cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. 

 POA members work together to establish and optimize standards of care for molecular testing through research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients, Irving, Texas-based Caris said. 

“St. Luke’s University Health Network is excited to join Caris’ Precision Oncology Alliance and partner with key academic and clinical institutions similarly dedicated to advancing precision medicine and biomarker research,” said Dr. Israel Zighelboim, interim chair, Department of Oncology – Cancer Center director, St. Luke’s University Health Network. 

The POA includes 72 cancer centers and academic institutions. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology, Caris said. 

“The Caris Precision Oncology Alliance is thrilled to welcome St. Luke’s University Health Network as a new member as we continue our growth,” said Dr. Chadi Nabhan, chairman of the Caris Precision Oncology Alliance. “This expanded collaborative effort of institutions from across the country continues to lead to innovative research to improve the outcomes of patients with cancer.” 

By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through Caris molecular profiling, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients, Nabhan said.  

POA members are also able to integrate with a growing portfolio of biomarker directed trials sponsored by biopharma.  

Additionally, as a member of the POA, institutions have access to Caris CODEai, the most comprehensive data solution in the industry with cancer treatment information and clinical outcomes data for over 275,000 patients covering over 1 million data points per patient, Caris said.